Log in to search using one of your social media accounts:

 

Differential Gene Expression in Prostate Tissue According to Ejaculation Frequency
Publication date: Available online 18 May 2018 Source:European Urology Author(s): Jennifer A. Sinnott, Katherine Brumberg, Kathryn M. Wilson, Ericka M. Ebot, Edward L. Giovannucci, Lorelei A. Mucci, Jennifer R. Rider In a prospective study of 31 925 men with 18 yr of follow-up, higher ejaculation frequency (EF) throughout adulthood was associated with lower rates of prostate cancer. To further explore this association, we evaluated whole transcriptome gene expression in the prostate tissue from study participants who developed prostate cancer between 1992 and 2004 (n =157 tumor tissue, n =85 adjacent normal). We tested fo...
Source: European Urology - May 19, 2018 Category: Urology & Nephrology Source Type: research

Adjuvant Vascular Endothelial Growth Factor –targeted Therapy in Renal Cell Carcinoma: A Systematic Review and Pooled Analysis
Conclusions This pooled analysis of reported randomized trials did not reveal a statistically significant effect between adjuvant VEGFR-targeted therapy and improved DFS or OS in patients with intermediate/high-risk local or regional fully resected RCC. Improvement in DFS may be more likely with the use of full-dose regimens, pending further results. However, adjuvant treatment was associated with high-grade AEs. Patient summary Vascular endothelial growth factor receptor–targeted therapy after nephrectomy for localized kidney cancer is not associated with consistent improvements in delaying cancer recurrence or prol...
Source: European Urology - May 19, 2018 Category: Urology & Nephrology Source Type: research

Randomized Trial Comparing Open Radical Cystectomy and Robot-assisted Laparoscopic Radical Cystectomy: Oncologic Outcomes
Conclusions The secondary outcomes from our randomized trial did not definitively demonstrate differences in cancer outcomes in patients treated with ORC or RARC. However, differences in observed patterns of first recurrence highlight the need for future studies. Patient summary Of 118 patients randomly assigned to undergo radical cystectomy/pelvic lymphadenectomy and urinary diversion, half were assigned to open surgery and half to robot-assisted techniques. We found no difference in risk of recurring or dying of bladder cancer between the two groups. In this secondary analysis of cancer outcomes from our randomized contr...
Source: European Urology - May 19, 2018 Category: Urology & Nephrology Source Type: research

Time for a “Radical” Change to Active Surveillance for Prostate Cancer?
Publication date: Available online 17 May 2018 Source:European Urology Author(s): Jenny L. Donovan, Freddie C. Hamdy (Source: European Urology)
Source: European Urology - May 18, 2018 Category: Urology & Nephrology Source Type: research

A Contemporary Prostate Biopsy Risk Calculator Based on Multiple Heterogeneous Cohorts
Conclusions The PBCG model should be used in place of the PCPTRC for prediction of prostate biopsy outcome. Patient summary A contemporary risk tool for outcomes on prostate biopsy based on the routine clinical risk factors is now available for informed decision-making. A North American multicohort-based risk tool for predicting prostate cancer outcomes on biopsy has been developed and outperformed a leading North American risk tool in validation. It is now available online for patients and their providers. (Source: European Urology)
Source: European Urology - May 17, 2018 Category: Urology & Nephrology Source Type: research

Re: Jochen Walz. The “PROMIS” of Magnetic Resonance Imaging Cost Effectiveness in Prostate Cancer Diagnosis? Eur Urol 2018;73:31–2
Publication date: June 2018 Source:European Urology, Volume 73, Issue 6 Author(s): Rita Faria, Marta O. Soares, Eldon Spackman, Hashim U. Ahmed, Louise C. Brown, Richard Kaplan, Mark Emberton, Mark J. Sculpher (Source: European Urology)
Source: European Urology - May 16, 2018 Category: Urology & Nephrology Source Type: research

Re: Repair of Damaged Ligaments with Tissue Fixation System Minisling Is Sufficient to Cure Major Prolapse in All Three Compartments: 5-yr Data
Publication date: June 2018 Source:European Urology, Volume 73, Issue 6 Author(s): Peter Emanuel Petros (Source: European Urology)
Source: European Urology - May 16, 2018 Category: Urology & Nephrology Source Type: research

Re: Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
Publication date: June 2018 Source:European Urology, Volume 73, Issue 6 Author(s): Izak Faiena, Amirali Salmasi, Allan J. Pantuck, Alexandra Drakaki (Source: European Urology)
Source: European Urology - May 16, 2018 Category: Urology & Nephrology Source Type: research

Re: A Randomized Study of Intraoperative Autologous Retropubic Urethral Sling on Urinary Control After Robotic Assisted Radical Prostatectomy
Publication date: June 2018 Source:European Urology, Volume 73, Issue 6 Author(s): Riccardo Lombardo, J.L.H. Ruud Bosch, Fiona C. Burkhard, Andrea Tubaro (Source: European Urology)
Source: European Urology - May 16, 2018 Category: Urology & Nephrology Source Type: research

Re: A Novel Tool for Predicting Extracapsular Extension During Graded Partial Nerve Sparing in Radical Prostatectomy
Publication date: June 2018 Source:European Urology, Volume 73, Issue 6 Author(s): Rodolfo Montironi, Liang Cheng, Antonio Lopez-Beltran, Marina Scarpelli, Francesco Montorsi (Source: European Urology)
Source: European Urology - May 16, 2018 Category: Urology & Nephrology Source Type: research

Re: Duration of Urethral Catheterization After Urethroplasty: How Long Is Enough?
Publication date: June 2018 Source:European Urology, Volume 73, Issue 6 Author(s): Francisco E. Martins, Pedro Simoes de Oliveira (Source: European Urology)
Source: European Urology - May 16, 2018 Category: Urology & Nephrology Source Type: research

Re: Management of the Urologic Sepsis Syndrome
Publication date: June 2018 Source:European Urology, Volume 73, Issue 6 Author(s): Carl A. Olsson (Source: European Urology)
Source: European Urology - May 16, 2018 Category: Urology & Nephrology Source Type: research

Association Between Lead Time and Prostate Cancer Grade: Evidence of Grade Progression from Long-term Follow-up of Large Population-based Cohorts Not Subject to Prostate-specific Antigen Screening
Conclusions Our data support grade progression, whereby following a prostate over time would reveal transitions from benign to low-grade and then high-grade PCa. Patient summary Men with a longer lead time between elevated prostate-specific antigen and subsequent prostate cancer diagnosis were more likely to have high-grade cancers at diagnosis. The probability that a cancer will be of high grade at diagnosis increases with the lead time. Our findings provide evidence of grade progression, whereby a prostate followed over time would exhibit transitions from benign to low-grade to high-grade prostate cancer. (Source: European Urology)
Source: European Urology - May 16, 2018 Category: Urology & Nephrology Source Type: research

Robotic Intracorporeal Padua Ileal Bladder: Surgical Technique, Perioperative, Oncologic and Functional Outcomes
Conclusions Our experience supports the feasibility of totally intracorporeal neobladder following RARC. Operative times and perioperative complication rates are likely to be reduced with increasing experience. Patient summary We report the outcomes of our first 45 consecutive patients who underwent robot-assisted radical cystectomy with intracorporeal neobladders. Perioperative, oncologic, and functional outcomes support this technique as a feasible and safe surgical option in tertiary referral centres. Our experience supports the feasibility of totally-intracorporeal neobladder following robotic radical cystectomy. Robot...
Source: European Urology - May 16, 2018 Category: Urology & Nephrology Source Type: research

Oral Pain and Morbidity with Buccal Mucosa Grafts for Substitution Urethroplasty: Closure or Not
Publication date: June 2018 Source:European Urology, Volume 73, Issue 6 Author(s): Christopher R. Chapple (Source: European Urology)
Source: European Urology - May 16, 2018 Category: Urology & Nephrology Source Type: research

Substitution Urethroplasty with Closure Versus Nonclosure of the Buccal Mucosa Graft Harvest Site: A Randomized Controlled Trial with a Detailed Analysis of Oral Pain and Morbidity
Conclusions NC is noninferior to C of the donor site in intensity and quality of oral pain, and offers a treatment alternative. Time from BMGU and length of the buccal mucosa graft have effects on oral morbidity and complications. Patient summary We investigated pain, morbidity, and complications following closure (C) versus nonclosure (NC) of the buccal mucosa harvest site in patients undergoing buccal mucosa graft urethroplasty (BMGU). We found that NC is not worse than C regarding oral pain. In addition, time from BMGU and length of the buccal mucosa graft have effects on oral morbidity and complications. We investigate...
Source: European Urology - May 16, 2018 Category: Urology & Nephrology Source Type: research

Non –risk-adapted Surveillance for Stage I Testicular Cancer: Critical Review and Summary
Conclusions NRAS is an attractive management option for men with CSITC, which maintains outstanding long-term cancer cure while sparing most patients treatment by avoiding prophylactic chemotherapy, radiation, or surgery. Patient summary Men with clinically localized (stage I) testicular cancer have an excellent prognosis, regardless of management. Non–risk-adapted active surveillance is an attractive management option where only patients destined to relapse will receive any treatment following orchiectomy. However, individual patient preferences should be discussed in selecting a management strategy. Men with clinic...
Source: European Urology - May 16, 2018 Category: Urology & Nephrology Source Type: research

Survival Outcomes of Men with Lymph Node-positive Prostate Cancer After Radical Prostatectomy: A Comparative Analysis of Different Postoperative Management Strategies
Conclusions In men with LNM after RP, ADT+EBRT improved survival over either observation or adjuvant ADT alone. This survival benefit increases with higher-risk disease. Patient summary Lymph node metastasis following radical prostatectomy is associated with poor survival outcomes. However, we found that adjuvant androgen deprivation therapy with external beam radiation therapy improved survival in these patients. Lymph node metastasis following radical prostatectomy is associated with poor survival outcomes. Adjuvant androgen deprivation therapy with external beam radiation therapy confers a long-term overall survival adv...
Source: European Urology - May 16, 2018 Category: Urology & Nephrology Source Type: research

Multiparametric Magnetic Resonance Imaging Is an Independent Predictor of Salvage Radiotherapy Outcomes After Radical Prostatectomy
Conclusions Pre-sXRT mpMRI improves clinicopathologic variables to estimate sXRT success, particularly in the early sXRT setting. Patient summary Men who have biochemically recurrent prostate cancer after radical prostatectomy often receive salvage radiotherapy. In our study, multiparametric pelvic magnetic resonance imaging prior to salvage radiotherapy was a significant predictor of prostate-specific antigen failure and metastasis after radiotherapy. Multiparametric magnetic resonance imaging (mpMRI) before salvage radiotherapy is a valuable prognostic adjunct to current clinicopathologic variables. Negative mpMRI was an...
Source: European Urology - May 16, 2018 Category: Urology & Nephrology Source Type: research

Docetaxel Versus Surveillance After Radical Prostatectomy for High-risk Prostate Cancer: Results from the Prospective Randomised, Open-label Phase 3 Scandinavian Prostate Cancer Group 12 Trial
Conclusions Docetaxel without hormonal therapy did not significantly improve biochemical disease-free survival after radical prostatectomy. Patient summary In this randomised trial, we tested whether chemotherapy after surgery for high-risk prostate cancer decreases the risk of a rising prostate-specific antigen. We found no benefit from docetaxel given after radical prostatectomy. In this randomised trial, docetaxel without hormonal therapy or continuous corticosteroids was given after radical prostatectomy for high-risk prostate cancer. We found no benefit from docetaxel alone given after radical prostatectomy. (Source: European Urology)
Source: European Urology - May 16, 2018 Category: Urology & Nephrology Source Type: research

Active Surveillance Offers Functional Advantages Without Impacting Survival for Low-risk Prostate Cancer
Publication date: June 2018 Source:European Urology, Volume 73, Issue 6 Author(s): Stacy Loeb (Source: European Urology)
Source: European Urology - May 16, 2018 Category: Urology & Nephrology Source Type: research

Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies
Conclusions There was no apparent survival benefit in the CHAARTED and GETUG-AFU15 studies with D for LV. Across both studies, early D showed consistent effect and improved OS in HV patients. Patient summary Patients with a higher burden of metastatic prostate cancer starting androgen deprivation therapy (ADT) have a poorer prognosis and are more likely to benefit from early docetaxel. Low-volume patients have longer overall survival with ADT alone, and the toxicity of docetaxel may outweigh its benefits. The aggregate data of two phase 3 trials show that patients with a high volume of metastatic castrate naive prostate ca...
Source: European Urology - May 16, 2018 Category: Urology & Nephrology Source Type: research

Comparison of Abiraterone Acetate and Docetaxel with Androgen Deprivation Therapy in High-risk and Metastatic Hormone-na ïve Prostate Cancer: A Systematic Review and Network Meta-analysis
Conclusions We did not identify a significant difference in OS between Abi-ADT and Doce-ADT for men with hormone-naïve high-risk or metastatic PCa, although Bayesian analysis demonstrates a high likelihood that Abi-ADT was preferred. Patient summary We synthesized the evidence available from studies examining the administration of docetaxel or abiraterone in combination with hormonal therapy for patients with newly diagnosed, advanced prostate cancer. While these studies did not directly compare these agents, we used methodological techniques to indirectly compare them and found no significant difference in overall su...
Source: European Urology - May 16, 2018 Category: Urology & Nephrology Source Type: research

Large-scale Sequencing of Testicular Germ Cell Tumour (TGCT) Cases Excludes Major TGCT Predisposition Gene
Publication date: June 2018 Source:European Urology, Volume 73, Issue 6 Author(s): Kevin Litchfield, Chey Loveday, Max Levy, Darshna Dudakia, Elizabeth Rapley, Jeremie Nsengimana, D. Tim Bishop, Alison Reid, Robert Huddart, Peter Broderick, Richard S. Houlston, Clare Turnbull Testicular germ cell tumour (TGCT), the most common cancer in young men, has a significant heritable basis that has long raised questions as to the existence of underlying major high-penetrance susceptibility gene(s). To determine the contribution of rare gene mutations to the inherited risk of TGCT, we analysed germline whole-exome data for 919 TGCT...
Source: European Urology - May 16, 2018 Category: Urology & Nephrology Source Type: research

How Should a Man with Prostate Cancer Choose his Surgeon?
Publication date: June 2018 Source:European Urology, Volume 73, Issue 6 Author(s): Matthew R. Cooperberg (Source: European Urology)
Source: European Urology - May 16, 2018 Category: Urology & Nephrology Source Type: research

Expression of Androgen Receptor Splice Variant 7 or 9 in Whole Blood Does Not Predict Response to Androgen-Axis –targeting Agents in Metastatic Castration-resistant Prostate Cancer
Publication date: June 2018 Source:European Urology, Volume 73, Issue 6 Author(s): Sarah Q. To, Edmond M. Kwan, Heidi C. Fettke, Andrew Mant, Maria M. Docanto, Luciano Martelotto, Patricia Bukczynska, Nicole Ng, Lisa-Jane K. Graham, Phillip Parente, Carmel Pezaro, Kate Mahon, Lisa Horvath, Tilman Todenhöfer, Arun A. Azad In 2014, a landmark study was published demonstrating that the expression of androgen receptor splice variant (AR-V) 7 was a negative predictive biomarker for response to abiraterone acetate and enzalutamide in metastatic castration-resistant prostate cancer (mCRPC) patients. However, these results w...
Source: European Urology - May 16, 2018 Category: Urology & Nephrology Source Type: research

The Risks of Theft and Copyright Breach from Camera Use During Scientific Presentations: It's Time for a Debate
Publication date: June 2018 Source:European Urology, Volume 73, Issue 6 Author(s): Sophie Rintoul-Hoad, Andrew Shindler, Gordon H. MuirPhotographs are frequently taken during urological presentations and distributed on social media; they may represent a breach of copyright and, in instances of clinical photographs, a breach of data protection and human rights laws. Presenters and delegates attending conferences should be advised of the conference's copyright policies. Acceptable use of camera phones during scientific presentations should be debated by the scientific community. (Source: European Urology)
Source: European Urology - May 16, 2018 Category: Urology & Nephrology Source Type: research

Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting And Data System)
Conclusions We hope that VI-RADS will standardize reporting, facilitate comparisons between patients, and in future years, will be tested and refined if necessary. While we do not advocate mpMRI for all patients with BC, this imaging may compliment pathology or reduce radiation-based imaging. Bladder mpMRI may be most useful in patients with non–muscle-invasive cancers, in expediting radical treatment or for determining response to bladder-sparing approaches. Patient summary Magnetic resonance imaging (MRI) scans for bladder cancer are becoming more common and may provide accurate information that helps improve patie...
Source: European Urology - May 11, 2018 Category: Urology & Nephrology Source Type: research

Reply to Taimur T. Shah, Graeme MacLennan, Rob Pickard, Samuel McClinton and Veeru Kasivisvanathan's Letter to the Editor re: Zhangqun Ye, Guohua Zeng, Huan Yang, et al. Efficacy and Safety of Tamsulosin in Medical Expulsive Therapy for Distal Ureteral Stones with Renal Colic: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial. Eur Urol 2018;73:385 –91
Publication date: Available online 9 May 2018 Source:European Urology Author(s): Zhangqun Ye, Guohua Zeng, Zhiqiang Chen, Hua Xu (Source: European Urology)
Source: European Urology - May 10, 2018 Category: Urology & Nephrology Source Type: research

Financial Conflicts of Interest Among Authors of Urology Clinical Practice Guidelines
Conclusions Many of the AUA guideline authors received payments from industry, some in excess of $50 000. A significant portion of disclosure statements were inaccurate, indicating a need for more stringent enforcement of the AUA disclosure policy. Patient summary Pharmaceutical company payments to doctors have been shown to influence how doctors treat patients. If these doctors are charged with making clinical recommendations to other doctors, in the form of clinical practice guidelines, the issue of industry payments becomes more severe. We found that many urologists on guideline panels receive money from industry and th...
Source: European Urology - May 8, 2018 Category: Urology & Nephrology Source Type: research

Influence of an International Consensus Conference on Practice Patterns in Advanced Prostate Cancer
Publication date: Available online 3 May 2018 Source:European Urology Author(s): Jun Gong, Aurelius Omlin, Sumanta K. Pal, J. Hsu, Bertrand Tombal, Matthew R. Sydes, Silke Gillessen (Source: European Urology)
Source: European Urology - May 4, 2018 Category: Urology & Nephrology Source Type: research

Re: Tobias Nordstr öm, Andrew Vickers, Melissa Assel, Hans Lilja, Henrik Grönberg, Martin Eklund. Comparison Between the Four-kallikrein Panel and Prostate Health Index for Predicting Prostate Cancer. Eur Urol 2015;68:139–46
Publication date: Available online 3 May 2018 Source:European Urology Author(s): Andrew Vickers, Tobias Nordström, Melissa Assel, Hans Lilja, Henrik Grönberg, Martin Eklund (Source: European Urology)
Source: European Urology - May 4, 2018 Category: Urology & Nephrology Source Type: research

Palliative Radical Prostatectomy in Men with Metastatic Castration-resistant Prostate Cancer: Only When Your Back Is Against the Wall!
Publication date: Available online 3 May 2018 Source:European Urology Author(s): Sophie Knipper, Markus Graefen (Source: European Urology)
Source: European Urology - May 4, 2018 Category: Urology & Nephrology Source Type: research

Positron Emission Tomography/Computed Tomography with 89Zr-girentuximab Can Aid in Diagnostic Dilemmas of Clear Cell Renal Cell Carcinoma Suspicion
Publication date: Available online 3 May 2018 Source:European Urology Author(s): Marlène C.H. Hekman, Mark Rijpkema, Erik H. Aarntzen, Sasja F. Mulder, Johan F. Langenhuijsen, Egbert Oosterwijk, Otto C. Boerman, Wim J.G. Oyen, Peter F.A. Mulders Based on the high expression of carbonic anhydrase IX (CAIX) in 95% of clear cell renal cell carcinoma (ccRCC), the anti-CAIX monoclonal antibody girentuximab can be used for the detection of ccRCC. This clinical study explores the value of 89Zr-labeled girentuximab positron emission tomography/computed tomography (PET/CT) imaging in diagnostic challenges regarding ccRCC. P...
Source: European Urology - May 3, 2018 Category: Urology & Nephrology Source Type: research

Outcomes for Patients with Node-positive Penile Cancer: Impact of Perioperative Systemic Therapies and the Importance of Surgical Intervention
Publication date: Available online 3 May 2018 Source:European Urology Author(s): Juan Chipollini, Andrea Necchi, Philippe E. Spiess (Source: European Urology)
Source: European Urology - May 3, 2018 Category: Urology & Nephrology Source Type: research

Mirabegron versus Antimuscarinics in the Treatment of Overactive Bladder: The Final Answer?
Publication date: Available online 1 May 2018 Source:European Urology Author(s): Tom A.T. Marcelissen, Gommert A. Van Koeveringe (Source: European Urology)
Source: European Urology - May 2, 2018 Category: Urology & Nephrology Source Type: research

Focal Therapy for Prostate Cancer: A More Vehement View of the Approach Could Translate into Real Benefits for Our Patients
Publication date: Available online 1 May 2018 Source:European Urology Author(s): Rafael Sanchez-Salas, Jean de la Rosette, Thomas J. Polascik, Arie Carneiro, Arjun Sivaraman, Xavier Cathelineau, Jochen WalzThe literature on focal therapy is currently insufficient to recommend it as first-line treatment. We need information from both randomised controlled trials and prospective registries for every available energy. That said, important research is under way in this field, and the door should be kept open to an approach that has the potential to offer adequate cancer control with lower morbidity and better post-treatment q...
Source: European Urology - May 2, 2018 Category: Urology & Nephrology Source Type: research

Impact of Adjuvant Radiotherapy in Node-positive Prostate Cancer Patients: The Importance of Patient Selection
This study aimed to test the external validity of our previous findings using a nationwide database while focusing on overall mortality as an endpoint. To this end, we identified 5498 pN1 PCa patients who were treated with RP, pelvic lymph node dissection, and androgen deprivation therapy with or without aRT, within the National Cancer Database, between 2004 and 2015. Patients were divided into five groups based on our previously published algorithm. Similar to our previous report, multivariable Cox regression analysis showed that only two of these groups benefit from aRT: (1) those with one to two positive nodes, patholog...
Source: European Urology - May 1, 2018 Category: Urology & Nephrology Source Type: research

Re: Massimiliano Spaliviero, Nicholas E. Power, Katie S. Murray, et al. Intravenous Mannitol Versus Placebo During Partial Nephrectomy in Patients with Normal Kidney Function: A Double-blind, Clinically-integrated, Randomized Trial. Eur Urol 2018;73:53 –9
Publication date: Available online 30 April 2018 Source:European Urology Author(s): Deepansh Dalela, Firas Abdollah, Craig Rogers (Source: European Urology)
Source: European Urology - May 1, 2018 Category: Urology & Nephrology Source Type: research

Re: Michael B. Atkins, Elizabeth R. Plimack, Igor Puzanov, et al. Axitinib in Combination with Pembrolizumab in Patients with Advanced Renal Cell Cancer: A Non-randomised, Open-label, Dose-finding, and Dose-expansion Phase 1b Trial. Lancet Oncol 2018;19:405 –15
Publication date: Available online 27 April 2018 Source:European Urology Author(s): Vincenzo Di Nunno, Matteo Santoni, Francesco Massari (Source: European Urology)
Source: European Urology - April 28, 2018 Category: Urology & Nephrology Source Type: research

Re: Characterization of Clinical Cases of Advanced Papillary Renal Cell Carcinoma via Comprehensive Genomic Profiling
Publication date: Available online 26 April 2018 Source:European Urology Author(s): Yunze Xu, Jin Zhang, Yiran Huang (Source: European Urology)
Source: European Urology - April 26, 2018 Category: Urology & Nephrology Source Type: research

Risks and Benefits of Adjuvant Radiotherapy After Inguinal Lymphadenectomy in Node-positive Penile Cancer: A Systematic Review by the European Association of Urology Penile Cancer Guidelines Panel
Conclusions The evidence indicates that men treated with AIRT do not gain benefit with respect to relapse or survival. Uncertainty remains due to the retrospective nature and high risks of bias across the evidence. Given the lack of evidence supporting AIRT, it cannot be recommended for routine practice. Patient summary Men with penile cancer who have involvement of the inguinal lymph nodes are at a high risk of cancer recurrence and death. We reviewed the literature to see if radiation treatment after removal of the nodes provided benefit. We did not find any good-quality evidence supporting this treatment, and hence it c...
Source: European Urology - April 25, 2018 Category: Urology & Nephrology Source Type: research

Efficacy and Tolerability of Mirabegron Compared with Antimuscarinic Monotherapy or Combination Therapies for Overactive Bladder: A Systematic Review and Network Meta-analysis
Conclusions The relief of key OAB symptoms produced by mirabegron 50mg is significantly better than placebo, and similar to a range of common antimuscarinics, with the benefit of significantly fewer bothersome anticholinergic side effects such as dry mouth. Combination treatment of solifenacin 5mg plus mirabegron 25 or 50mg appears to provide an efficacy benefit compared with mirabegron 50mg, with the expected side effects of individual antimuscarinics. Patient summary This study assessed the efficacy and tolerability of different drug treatments for OAB. Mirabegron 50mg was as effective as antimuscarinic therapy, with few...
Source: European Urology - April 24, 2018 Category: Urology & Nephrology Source Type: research

Treatment Options for Patients with Recurrent Tumors After BCG Therapy: Are We Ignoring the Obvious?
Publication date: Available online 22 April 2018 Source:European Urology Author(s): Roger Li, Philippe E. Spiess, Ashish M. KamatTreatment options are limited for non–muscle-invasive bladder cancer patients having failed BCG treatment who cannot undergo cystectomy. While results from ongoing clinical trials are awaited, data have emerged suggesting that combination of agents having previously demonstrated safety and efficacy in this setting can help a large percentage of our patients. These data should not be ignored. (Source: European Urology)
Source: European Urology - April 23, 2018 Category: Urology & Nephrology Source Type: research

Active Surveillance of Small Renal Masses: A Safe Management Strategy for Select Patients
Publication date: Available online 21 April 2018 Source:European Urology Author(s): Mohit Gupta, Hiten D. Patel, Phillip M. Pierorazio (Source: European Urology)
Source: European Urology - April 22, 2018 Category: Urology & Nephrology Source Type: research

Can Negative Prostate Magnetic Resonance Imaging Give Us the Reassurance We Need To Avoid Standard Biopsy? An Evidence-based Practical Approach
Publication date: Available online 21 April 2018 Source:European Urology Author(s): Caroline Moore (Source: European Urology)
Source: European Urology - April 22, 2018 Category: Urology & Nephrology Source Type: research

Re: Surveillance or Metastasis-directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial
Publication date: Available online 19 April 2018 Source:European Urology Author(s): Jochen Walz (Source: European Urology)
Source: European Urology - April 19, 2018 Category: Urology & Nephrology Source Type: research

Re: Ibuprofen Alters Human Testicular Physiology To Produce a State of Compensated Hypogonadism
Publication date: Available online 19 April 2018 Source:European Urology Author(s): Jonathan Katz, Atil Y. Kargi, Ranjith Ramasamy (Source: European Urology)
Source: European Urology - April 19, 2018 Category: Urology & Nephrology Source Type: research

The New Standard: Personalised Information about the Risks and Benefits of Treatment Strategies for Localised Prostate Cancer
Publication date: Available online 13 April 2018 Source:European Urology Author(s): Marie-Anne van Stam, Henk van der Poel (Source: European Urology)
Source: European Urology - April 14, 2018 Category: Urology & Nephrology Source Type: research

Reply to Francesco Massari and Vincenzo Di Nunno's Letter to the Editor re: Jose Luis Perez-Gracia, Yohann Loriot, Jonathan E. Rosenberg, et al. Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens. Eur Urol 2018;73:462 –8
Publication date: Available online 13 April 2018 Source:European Urology Author(s): Jose Luis Perez-Gracia (Source: European Urology)
Source: European Urology - April 14, 2018 Category: Urology & Nephrology Source Type: research